Literature DB >> 20087631

New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma.

Henri de Martimprey1, Jean-Rémi Bertrand, Claude Malvy, Patrick Couvreur, Christine Vauthier.   

Abstract

PURPOSE: Development of efficient in vivo delivery nanodevices remains a major challenge to achieve clinical application of siRNA. The present study refers to the conception of core-shell nanoparticles aiming to make possible intravenous administration of chemically unmodified siRNA oriented towards the junction oncogene of the papillary thyroid carcinoma.
METHODS: Nanoparticles were prepared by redox radical emulsion polymerization of isobutylcyanoacrylate and isohexylcyanoacrylate with chitosan. The loading of the nanoparticles with siRNA was achieved by adsorption. The biological activity of the siRNA-loaded nanoparticles was assessed on mice bearing a papillary thyroid carcinoma after intratumoral and intravenous administration.
RESULTS: Chitosan-coated nanoparticles with a diameter of 60 nm were obtained by adding 3% pluronic in the preparation medium. siRNA were associated with the nanoparticles by surface adsorption. In vivo, the antisense siRNA associated with the nanoparticles lead to a strong antitumoral activity. The tumor growth was almost stopped after intravenous injection of the antisense siRNA-loaded nanoparticles, while in all control experiments, the tumor size was increased by at least 10 times.
CONCLUSION: This work showed that poly(alkylcyanoacrylate) nanoparticles coated with chitosan are suitable carriers to achieve in vivo delivery of active siRNA to tumor including after systemic administration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087631     DOI: 10.1007/s11095-009-0043-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

Review 1.  Parameters influencing the stealthiness of colloidal drug delivery systems.

Authors:  Arnaud Vonarbourg; Catherine Passirani; Patrick Saulnier; Jean-Pierre Benoit
Journal:  Biomaterials       Date:  2006-05-02       Impact factor: 12.479

Review 2.  Delivery vehicles for small interfering RNA in vivo.

Authors:  Antonin R de Fougerolles
Journal:  Hum Gene Ther       Date:  2008-02       Impact factor: 5.695

Review 3.  RNAi therapeutics: an update on delivery.

Authors:  Thu Nguyen; Ellen M Menocal; Jens Harborth; Johannes H Fruehauf
Journal:  Curr Opin Mol Ther       Date:  2008-04

Review 4.  Exploiting the enhanced permeability and retention effect for tumor targeting.

Authors:  Arun K Iyer; Greish Khaled; Jun Fang; Hiroshi Maeda
Journal:  Drug Discov Today       Date:  2006-09       Impact factor: 7.851

Review 5.  Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer.

Authors:  Martin Meyer; Ernst Wagner
Journal:  Hum Gene Ther       Date:  2006-11       Impact factor: 5.695

6.  Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma.

Authors:  Nedjma Toub; Jean-Rémi Bertrand; Ali Tamaddon; Hind Elhamess; Hervé Hillaireau; Andrei Maksimenko; Jean Maccario; Claude Malvy; Elias Fattal; Patrick Couvreur
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

7.  Preparation of semi-interpenetrating polymer networks composed of chitosan and poloxamer.

Authors:  In-Yong Kim; Mi-Kyong Yoo; Bom-Chol Kim; Se-Kwon Kim; Hyun-Chul Lee; Chong-Su Cho
Journal:  Int J Biol Macromol       Date:  2006-01-26       Impact factor: 6.953

8.  Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice.

Authors:  Xu-Li Wang; Rongzuo Xu; Xueming Wu; David Gillespie; Randy Jensen; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

9.  siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma.

Authors:  Henri de Martimprey; Jean-Remi Bertrand; Alfredo Fusco; Massimo Santoro; Patrick Couvreur; Christine Vauthier; Claude Malvy
Journal:  Nucleic Acids Res       Date:  2007-12-13       Impact factor: 16.971

Review 10.  RNA interference: an emerging generation of biologicals.

Authors:  Neeta Shrivastava; Anshu Srivastava
Journal:  Biotechnol J       Date:  2008-03       Impact factor: 4.677

View more
  5 in total

1.  Counterion of Chitosan Influences Thermodynamics of Association of siRNA with a Chitosan-Based siRNA Carrier.

Authors:  Christelle Zandanel; Magali Noiray; Christine Vauthier
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

Review 2.  Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.

Authors:  Maria Sofia Falzarano; Chiara Passarelli; Alessandra Ferlini
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

3.  Efficient Gene Silencing by Self-Assembled Complexes of siRNA and Symmetrical Fatty Acid Amides of Spermine.

Authors:  Abdelkader A Metwally; Charareh Pourzand; Ian S Blagbrough
Journal:  Pharmaceutics       Date:  2011-03-25       Impact factor: 6.321

4.  Stromal interaction molecule 1 (STIM1) knock down attenuates invasion and proliferation and enhances the expression of thyroid-specific proteins in human follicular thyroid cancer cells.

Authors:  Muhammad Yasir Asghar; Taru Lassila; Ilkka Paatero; Van Dien Nguyen; Pauliina Kronqvist; Jixi Zhang; Anna Slita; Christoffer Löf; You Zhou; Jessica Rosenholm; Kid Törnquist
Journal:  Cell Mol Life Sci       Date:  2021-06-21       Impact factor: 9.261

5.  Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice.

Authors:  Elena Bassi; Sofia Falzarano; Marina Fabris; Francesca Gualandi; Luciano Merlini; Gaetano Vattemi; Daniela Perrone; Elena Marchesi; Patrizia Sabatelli; Katia Sparnacci; Michele Laus; Paolo Bonaldo; Paola Rimessi; Paola Braghetta; Alessandra Ferlini
Journal:  J Biomed Biotechnol       Date:  2012-10-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.